SSRI Effects on Depression and Immunity in HIV/AIDS
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a 10 week, double-blind, placebo controlled trial to evaluate SSRI (Selective
Serotonin Reuptake Inhibitor) effects for treatment of depression in HIV/AIDS with a focus on
innate immunity and inflammation. Depressed population is HIV + on cART (Combination
Antiretroviral Therapy), not currently on pharmacotherapy for depression. Subjects will
complete computerized cognitive behavior therapy, CCBT for their depression. Blood samples
collected for virologic, neuroendocrine, and immunologic evaluation. Our overarching
hypothesis is that SSRI treatment of depression and improvement of depressive symptoms leads
to increased innate immunity and decreased inflammation, resulting in better control of HIV
disease and decreased morbidity.